(RTTNews) - On Thursday, Biofrontera Inc. (BFRI) said it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking to expand the approved use of Ameluz in combination with photodynamic therapy (PDT) for the treatment of actinic keratoses (AKs).
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。